Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, affecting millions every year. While standard treatments have saved lives, the rise of drug-resistant TB threatens global progress. Now, more than ever, rapid and precise diagnosis is essential.

Defeating Drug-Resistant TB Together

Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose serious public health threats. Traditional diagnostic methods take weeks, delaying treatment and increasing transmission risks. The need for faster, more accurate solutions has never been greater.

SPIT SEQ: Revolutionizing TB Diagnosis

SPIT SEQ, an advanced Next-Generation Sequencing (NGS)-based Whole Genome Sequencing test, detects drug-resistant TB with unmatched accuracy. Unlike conventional methods, it analyses the entire Mycobacterium tuberculosis genome directly from clinical samples, providing rapid and comprehensive results.

Why SPIT SEQ is a Game-Changer

Rapid Results – Delivers a detailed drug-resistance profile in record time.
Comprehensive Detection – Identifies resistance to multiple anti-TB drugs.
Direct Sample Testing – Eliminates the need for lengthy culture-based methods.
Actionable Insights – Helps clinicians develop the most effective treatment strategies.

This World TB Day, we stand united in the fight against TB. SPIT SEQ is transforming diagnostics, ensuring timely interventions and improved treatment outcomes.